Literature DB >> 4548384

The status of measles after five years of mass vaccination in the USSR.

P N Burgasov, O G Andzaparidze, V F Popov.   

Abstract

Mass vaccination of children from 10 months to 8 years old with the original live vaccine prepared from the Leningrad-16 strain has led to a sharp decline in measles morbidity and mortality, and changed its epidemic pattern. In 1972, after 5 years of mass vaccination, the morbidity rate was 117.5 per 100 000 persons, whereas before vaccination the average annual morbidity rate was about 827.0. The periodicity of increases in morbidity every 3 years was also broken, the last peak of measles morbidity occurring in 1965. Another result of vaccination is that the formerly much higher morbidity rate in urban areas is now lower than that in rural areas. The mortality rate decreased more than 3-fold compared with the period before vaccination, and recently no deaths were registered in a number of regions. The serologic examination of 7 585 vaccinated children from 10 different regions revealed antibodies with a mean geometric titre of 78.6+/-1.16 in 90% of individuals. The high antibody level was maintained for 7 years after vaccination. The effect of vaccination is both epidemiological and economical. The saving in the use of gamma-globulin alone covered the cost of the vaccine and the expenses involved during vaccination.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4548384      PMCID: PMC2481016     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  1 in total

1.  Attenuated measles virus vaccine dosage study in Central Africa.

Authors:  A L Rosenbloom; M Taylor; H L Casey
Journal:  J Trop Med Hyg       Date:  1970-08
  1 in total
  3 in total

1.  Cost-benefit analysis and immunization programmes in developing countries.

Authors:  A L Creese; R H Henderson
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

2.  Chapter 8 Paramyxoviruses.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29

Review 3.  Vaccine platform recombinant measles virus.

Authors:  Michael D Mühlebach
Journal:  Virus Genes       Date:  2017-07-14       Impact factor: 2.332

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.